Vaccines. Robert Read University of Southampton University Hospital Southampton
|
|
- Elijah Welch
- 5 years ago
- Views:
Transcription
1 Vaccines Robert Read University of Southampton University Hospital Southampton
2 Disclosures Non personal, non specific; Novartis-GSK Member, JCVI Editor in Chief, Journal of Infection, and Current Opinion in Infectious Diseases
3 Question In the under 5s, since 2013 there has been `replacement` invasive pneumococcal disease caused by A serotype 4 B serotype 6 C serotype 9V D serotype 14 E serotype 22F
4 Question Since september 2015, adolescents have been receiving routinely the following meningococcal vaccine for the given reason A rmenb to cover serogroup B B rmen B to cover serogroup Y C MenC to cover serogroup C D conjacwy to cover serogroup W E conjacwy to cover serogroup Y
5 Routine Immunisation Schedule 2015
6 Routine Immunisation Schedule 2015
7 Selective immunisation programmes 2015
8 NIHR Southampton Respiratory Biomedical Research Unit The nasopharynx the root of all.. Pneumonia Otitis Media Sinusitis Chronic Bronchial Sepsis Meningitis
9 NIHR Southampton Respiratory Biomedical Research Unit The nasopharynx the root of all.. Pneumococcal carriage Ifedayo et al 2012 Meningococcal carriage Christensen et al 2010
10
11 Vaccine Name acronym nature serotypes 23-valent pneumococcal polysaccharide vaccine 7-valent pneumococcal glyco-conjugate vaccine 10-valent pneumococcal glyco-conjugate vaccine pneumovax PPV23 Plain Pneumococcal vaccines polysaccharide Prevnar PCV7 Conjugated to diphtheria protein (CRM197) Synflorix PCV10 Conjugated to NTHi protein D, or tetanus/diphthe ria proteins 1, 2, 3, 4, 5, 6b, 7F, 8,9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F 4, 6B, 9V, 14, 18C, 19F and 23F 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F 13-valent pneumococcal glyco-conjugate vaccine Prevnar 13 PCV13 Conjugated to diphtheria protein (CRM197) 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F
12 Vaccine Name acronym nature serotypes 23-valent pneumococcal polysaccharide vaccine 7-valent pneumococcal glyco-conjugate vaccine 10-valent pneumococcal glyco-conjugate vaccine pneumovax PPV23 Plain Pneumococcal vaccines polysaccharide Prevnar PCV7 Conjugated to diphtheria protein (CRM197) Synflorix PCV10 Conjugated to NTHi protein D, or tetanus/diphthe ria proteins 1, 2, 3, 4, 5, 6b, 7F, 8,9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F 4, 6B, 9V, 14, 18C, 19F and 23F 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F 13-valent pneumococcal glyco-conjugate vaccine Prevnar 13 PCV13 Conjugated to diphtheria protein (CRM197) 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F
13 Vaccine Name acronym nature serotypes 23-valent pneumococcal polysaccharide vaccine 7-valent pneumococcal glyco-conjugate vaccine 10-valent pneumococcal glyco-conjugate vaccine pneumovax PPV23 Plain Pneumococcal vaccines polysaccharide Prevnar PCV7 Conjugated to diphtheria protein (CRM197) Synflorix PCV10 Conjugated to NTHi protein D, or tetanus/diphthe ria proteins 1, 2, 3, 4, 5, 6b, 7F, 8,9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F 4, 6B, 9V, 14, 18C, 19F and 23F 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F 13-valent pneumococcal glyco-conjugate vaccine Prevnar 13 PCV13 Conjugated to diphtheria protein (CRM197) 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F
14 Figure 1. Corrected* invasive pneumococcal disease incidence from epidemiological year 2000/01 to 2013/14, by serotype grouping and agepcv7=seven-valent pneumococcal conjugate vaccine. PCV13=13-valent pneumococcal conjugate vaccine. NVT=nonvaccine type. *Corr... Waight PA Lancet Infect Dis 2015
15 NIHR Southampton Respiratory Biomedical Research Unit The nasopharynx the root of all.. Pneumococcal carriage Ifedayo et al 2012 Meningococcal carriage Christensen et al 2010
16 Pneumococcal Carriage Rates in Children Decline 3 Years After Implementation of PCV7 Vaccination 1 Cross-sectional observation study, healthy Dutch 11- and 24-month-olds prior to and post-pcv7 introduction 40% Streptococcus pneumoniae* Carriage in Children (%) 20% 11 months 24 months 0% Pre-vaccination Post-vaccination Time period nasopharyngeal swabs collected *Streptococcus pneumoniae serotypes included in 7-valent pneumococcal conjugate vaccine. 11-month-olds: Pre-PCV7 n=319, Post-PCV7 n=329; 24-month-olds: Pre-PCV7 n=321, Post-PCV7 n= Spijkerman J, et al. Emerg Infect Dis. 2011;17:
17 Changes in ranked serotype distribution in overall carriage in our findings from 2001/2002, 2008/2009 and 2012/2013. Van Hoek AJ, Vaccine 2014 Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England
18 Van Hoek AJ, Vaccine 2014
19 Figure 3. Number of invasive pneumococcal disease cases due to non-pcv13 serotypes in children younger than 5 years from July, 2012, to June, 2013, and from July, 2013, to June, 2014Serotypes 15B and 15C were combined because they are considered to be one rapi... Pauline A Waight, Nicholas J Andrews, Shamez N Ladhani, Carmen L Sheppard, Mary P E Slack, Elizabeth Miller Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study null, Volume 15, Issue 5, 2015,
20 Fig 3. Forest Plot of PPV23 efficacy to prevent all-cause CAP by study setting. Schiffner-Rohe J, Witt A, Hemmerling J, von Eiff C, Leverkus FW (2016) Efficacy of PPV23 in Preventing Pneumococcal Pneumonia in Adults at Increased Risk A Systematic Review and Meta-Analysis. PLoS ONE 11(1): e doi: /journal.pone
21 Post Hoc Analysis of the Cumulative Episodes of the Primary and Secondary Efficacy End Points in the Per- Protocol Population. Bonten MJ et al. N Engl J Med 2015;372:
22 Figure 1. Corrected* invasive pneumococcal disease incidence from epidemiological year 2000/01 to 2013/14, by serotype grouping and agepcv7=seven-valent pneumococcal conjugate vaccine. PCV13=13-valent pneumococcal conjugate vaccine. NVT=nonvaccine type. *Corr... Waight PA Lancet Infect Dis 2015
23 Neisseria meningitidis - groups Neisseria meningitidis strains are classified into 12 groups. The polysaccharide capsule is used to identify the different groups. A B C Five main groups cause the majority (95%) of all meningococcal disease around the world A, B, C, W and Y. Polysaccharide Capsule W Y MenB is responsible for ~85% of meningococcal disease in the England & Wales.
24 Meningococcal diseaseglobal epidemiology CANADA 1 EUROPE 5 RUSSIA 10 14% 23% 59% USA 2 13% 71% TURKEY 6 25% 26% 40% JAPAN 11 36% 28% 32% 18% 35% TAIWAN 12 21% 57% COLOMBIA 3 BRAZIL 3 SAUDI ARABIA 7 36% 35% 50% 29% 38% 29% 71% 21% 17% 78% AFRICAN MENINGITIS BELT 8 AUSTRALIA 13 ARGENTINA 4 43% 48% 10% 11% 47% 83% 27% NEW ZEALAND 14 48% SOUTH AFRICA 9 57% A B C W- 135 X Y Represents serogroups not defined for each individual country Generated from multiple refrences MEN-BEX-P-S
25 Structure of Meningococcal Outer Membrane, Showing Variability of Outer-Membrane Proteins and Capsule Used in Vaccines and Interaction with Complement. Tan LK et al. N Engl J Med 2010;362:
26 Invasive meningococcal disease in England and Wales by capsular group 2002/03 to 2011/12 (data provided by Public Health England)
27 Meningococcal conjugate vaccine production Vaccine 1999 C 2010 A C Y W 2010 A Polysaccharide capsule? B MenB polysaccharide is polysialic acid, a compound identical to that found on the surface of human neuronal cells. Consequently: (i) Poorly immunogenic. (ii) Potential to induce an autoimmune response.
28 Serogroup C Conjugate Vaccine Successfully Reduced Carriage of Serogroup C Meningococci (UK) 1 Immunised adolescents years of age Serogroup C 3 Meningococci (% of isolates) Serogroup B 1. Maiden MC, et al. J Infect Dis. 2008;197: % 81% Meningococci (% of isolates) Serogroup W-135 Serogroup Y 28
29 Figure 2 Areas of Chad vaccinated with PsA TT in 2011, or in epidemic or alert situation during Jan June 2012 Green shading shows the districts where mass vaccination of people aged 1 29 years was undertaken at the end of 2011, before the 2012 meningitis... DM Daugla, JP Gami, K Gamougam, N Naibei, L Mbainadji, M Narbé, J Toralta, B Kodbesse, C Ngadoua, ME... Effect of a serogroup A meningococcal conjugate vaccine (PsA TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study The Lancet null 2013 null
30 serogroup A carriers 32/4278 pre Serogroup A carriers 1/2001 post Figure 3 Incidence of reported cases of meningitis in Chad, Vaccination with PsA TT was undertaken in patients aged 1 29 years at the end of 2011 (arrow). PsA TT=serogroup A meningococcal polysaccharide tetanus toxoid conjugate vaccine. DM Daugla, JP Gami, K Gamougam, N Naibei, L Mbainadji, M Narbé, J Toralta, B Kodbesse, C Ngadoua, ME... Effect of a serogroup A meningococcal conjugate vaccine (PsA TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study The Lancet null 2013 null
31 Novel antigens discovered by reverse vaccinology Based on the genome sequence of MC58, 570 ORFs that potentially encoded novel surface exposed or exported proteins were identified ~350 proteins successfully expressed in E. coli, purified, and used to immunise mice IHT-C 2,200,000 2,100,000 2,000,000 1,900,000 1,800,000 1,700,000 1,600,000 1,500,000 1,400,000 1,300,000 1,200,000 Bexsero 1 100, ,000 1,000,000 1,100, , ,000 IHT-A 400, , , , ,000 IHT-B 28 novel protein antigens identified expression and purification purified proteins Sera used to confirm surface exposure of novel proteins immunisations Slide provided by Novartis Vaccines
32 Novartis MenB vaccine, Bexsero Previously known as 4CMenB or rmenb+omv. Contains 4 main antigens. Three recombinant proteins discovered by reverse vaccinology. OMVs from the New Zealand outbreak strain (NZ 98/254). + fhbp (Variant 1) NadA NHBA PorA
33 Routine Immunisation Schedule 2015
34 Study Methods Pre-licensure study to assess effect on carriage at an individual level Phase III, multi-centre, RCT 2,968 students from universities at 10 different UK sites 3 month enrolment (Sep Dec 2010) Subjects received either: 2 doses of 4CMenB (BEXSERO) 1 dose of MenACWY-CRM (MENVEO)/1 dose of saline placebo 2 doses of Japanese encephalitis (IXIARO) (control) Nasopharyngeal swabs taken at baseline, and at Months 1, 2, 4, 6 and 12 Carriage isolate characterisation performed at HPA (PHE) and Oxford University
35 Carriage Study Design Group 4CMenB (BEXSERO) (974 subjects)* Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Day 1 Month 1 Month 2 Month 4 Month 6 Month 12 Swab 4CMenB (BEXSERO) Swab 4CMenB (BEXSERO) Swab Swab Swab Swab MenACWY (MENVEO) Control (985 subjects)* Swab IXIARO (JEV) Swab IXIARO (JEV) Swab Swab Swab Swab MenACWY (MENVEO) MenACWY (MENVEO) (984 subjects)* Swab MenACWY (MENVEO) Swab Placebo Swab Swab Swab Swab *Subset (~600 subjects) evaluated for immunogenicity
36 Primary Analysis at 1 Month After the Vaccination Series (Read et al Lancet 2015) 4CMenB co-primary Carriage prevalence of virulent sequence types (ST)* of N. meningitidis capsular group B at 1 month following administration of 2 doses of 4CMenB Visit 3 [Month 2] Vaccine Groups Efficacy % 4CMenB Control (95% CI) Number % % 9.50% 8.08% N ( ) *Virulent ST types are those capsular group B ST types (or clonal complex members) causing disease in the UK ( ). MenACWY-CRM co-primary Carriage prevalence of N. meningitidis combined serogroups A, C, W and Y at 1 month following administration of a single dose of MenACWY-CRM Vaccine Groups Efficacy % MenACWY-CRM Control (95% CI) Visit 2 [Month 1] Number % % 5.87% 6.12% N ( ) Analyses adjusted for baseline carriage, treatment group, centre and significant risk factors as identified within the multivariate model.
37 MenACWY-CRM Carriage at Cumulative Later Sampling Points MenACWY-CRM secondary Carriage prevalence and calculated efficacy of combined serogroups CWY and serogroup Y across cumulative later timepoints (Visits 3 6) Vaccine Groups MenACWY- CRM Control Efficacy % (95% CI) C, W, Y Serogroupable Number % 5.5% 7.4% N % ( ) Y Serogroupable Number % 4.5% 6.5% N % ( ) MenACWY-CRM reduces nasopharyngeal carriage of N. meningitidis serogroup CWY strains Analyses adjusted for baseline carriage, treatment group, centre and significant risk factors as identified within the multivariate model.
38 4CMenB Carriage at Cumulative Later Sampling Points 4CMenB secondary Carriage prevalence and calculated efficacy for carriage of combined capsular groups BCWY or all N. meningitidis strains across cumulative later timepoints (Visits 4 6) B, C, W, Y Capsular group Vaccine Groups Efficacy % 4CMenB Control (95% CI) Number % % 18.0% 20.9% N ( ) Any N. meningitidis Number % 32.0% 34.4% N % ( ) 4CMenB reduces nasopharyngeal carriage of N. meningitidis capsular group BCWY strains Non-significant trends for virulent B strains (12.6%; p=0.350) and all ST B strains (15.6%; p=0.225) Analyses adjusted for baseline carriage, treatment group, centre and significant risk factors as identified within the multivariate model.
39 Serogroup W disease
40 Serogroup W disease, by age
41 Routine Immunisation Schedule 2015
42 Question In the under 5s, since 2013 there has been `replacement` invasive pneumococcal disease caused by A serotype 4 B serotype 6 C serotype 9V D serotype 14 E serotype 22F
43 Question In the under 5s, since 2013 there has been `replacement` invasive pneumococcal disease caused by A serotype 4 B serotype 6 C serotype 9V D serotype 14 E serotype 22F
44 Question Since september 2015, adolescents have been receiving routinely the following meningococcal vaccine for the given reason A rmenb to cover serogroup B B rmen B to cover serogroup Y C MenC to cover serogroup C D conjacwy to cover serogroup W E conjacwy to cover serogroup Y
45 Question Since september 2015, adolescents have been receiving routinely the following meningococcal vaccine for the given reason A rmenb to cover serogroup B B rmen B to cover serogroup Y C MenC to cover serogroup C D conjacwy to cover serogroup W E conjacwy to cover serogroup Y
46 Thankyou
47 Vaccines for Underlying medical conditions2015
ESCMID Online Lecture Library
What would be the best schedule for prevention of meningococcal disease in all ages? Ray Borrow ray.borrow@phe.gov.uk Public Health England, Manchester, UK MCC vaccine programme - UK In November 1999,
More informationBacterial diseases caused by Streptoccus pneumoniae in children
Bacterial diseases caused by Streptoccus pneumoniae in children Bactermia 85% Bacterial pneumonia 66% Bacterial meningitis 50% Otitis media 40% Paranasal sinusitis 40% 0% 10% 20% 30% 40% 50% 60% 70% 80%
More informationInvasive Meningococcal Disease - prevention through vaccination
Invasive Meningococcal Disease - prevention through vaccination Dr Shamez Ladhani Paediatric Infectious Diseases Consultant Public Health England Email: shamez.ladhani@phe.gov.uk a pain you cannot describe
More informationInvasive Meningococcal Disease - prevention through vaccination
Invasive Meningococcal Disease - prevention through vaccination Dr Shamez Ladhani Paediatric Infectious Diseases Consultant Public Health England Email: shamez.ladhani@phe.gov.uk a pain you cannot describe
More informationOutsourcing in Clinical Trials 1-2 July 2015
Outsourcing in Clinical Trials 1-2 July 2015 Innovating Dr Chris Bailey Babraham Research Campus Babraham Cambridge CB22 3AT UK +44 (0)1223 496115 Vaccines www.immbio.com 1 Utilising Academia for the Benefit
More informationPediatric and Adolescent Vaccines
Pediatric and Adolescent Vaccines Andrea A. Berry, M.D. Division of Infectious Diseases and Tropical Pediatrics Center for Vaccine Development & Division of Malaria Research Overview Pediatric vaccine
More informationMulticomponent MenB Vaccine (4CMenB): An Innovative Step In the Global Fight Against Serogroup B Meningococcal Disease
Multicomponent MenB Vaccine (4CMenB): An Innovative Step In the Global Fight Against Serogroup B Meningococcal Disease Jeffrey J. Stoddard, MD, FAAP Head, Global Medical Affairs Novartis Vaccines and Diagnostics
More informationMeningococcal disease and vaccination in the UK
Meningococcal disease and vaccination in the UK Ray Borrow Professor of Vaccine Preventable Diseases, Vaccine Evaluation Unit, Health Protection Agency, Manchester Royal Infirmary, Manchester, U.K. ray.borrow@hpa.org.uk
More informationBenefits of the pneumococcal immunisation programme in children in the United Kingdom
Benefits of the pneumococcal immunisation programme in children in the United Kingdom 2006-2014 Professor Mary P E Slack mpeslack@gmail.com March 2015 Disclosure of interest The presenter has received
More informationPneumococcal vaccination in UK: an update. Dr Richard Pebody Immunisation Department Health Protection Agency Centre for Infections
Pneumococcal vaccination in UK: an update Dr Richard Pebody Immunisation Department Health Protection Agency Centre for Infections Leading infectious causes of mortality, 2000 WHO estimates 3.5 Deaths
More informationMeningococcal vaccines and Herd protection. Potential Role, Coverage and Impact on carriage of the New Serogroup B protein vaccines in the Region
Meningococcal vaccines and Herd protection. Potential Role, Coverage and Impact on carriage of the New Serogroup B protein vaccines in the Region Ricardo Rüttimann Pediatric Infectious Diseases FUNCEI
More informationInvasive Meningococcal Disease - prevention through vaccination
Invasive Meningococcal Disease - prevention through vaccination Dr Shamez Ladhani Paediatric Infectious Diseases Consultant Public Health England Email: shamez.ladhani@phe.gov.uk Vaccines against MenB
More informationExperience with maternal pertussis and PCV13 immunisation in England
Experience with maternal pertussis and PCV13 immunisation in England Immunisation, Hepatitis & Blood Safety department Public Health England 5th RIVM Vaccine Preventable Diseases Research day 18 th November
More informationA Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program
Drugs (2014) 74:15 30 DOI 10.1007/s40265-013-0155-7 REVIEW ARTICLE A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program Miguel O Ryan Jeffrey Stoddard Daniela
More informationFULL PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BEXSERO safely and effectively. See full prescribing information for BEXSERO. BEXSERO (Meningococcal
More informationBiology of Neisseria meningitidis: implications for vaccine development Richard Moxon: University of Oxford
Biology of Neisseria meningitidis: implications for vaccine development Richard Moxon: University of Oxford Biology of N.meningitidis infection Within hours, the disease may progress to shock with multi-organ
More informationHemagglutinin Neuraminidase
Evolving Vaccine Guidance: Influenza, Meningococcal & HPV Vaccines H. Cody Meissner, M.D. Professor of Pediatrics Tufts University School of Medicine Maine Chapter AAP Bar Harbor, Maine October 16, 2016
More informationImmunisation Update for Occupational Health
Immunisation Update for Occupational Health Dr Gayatri Amirthalingam Immunisation, Hepatitis & Blood Safety department Public Health England 29 th April 2016 Session Outline Epidemiology of vaccine preventable
More information9/12/2018. Meningococcal Disease and Meningococcal Vaccine. Neisseria meningitidis. Meningococcal Disease Pathogenesis. Aerobic gram-negative bacteria
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Meningococcal Disease and Meningococcal Vaccine Adult Track Chapter 14 Photographs and images included
More informationImpact of vaccination on epidemiology in adults
Impact of vaccination on epidemiology in adults Jan Verhaegen 1. Data on prospective study on IPD in Belgium (2009-2011) 2. Evolution of capsular types of invasive isolates from adults after introduction
More informationPrevention of Meningococcal Disease. Marco Aurélio P. Sáfadi, MD, PhD FCM da Santa Casa de São Paulo
Prevention of Meningococcal Disease Marco Aurélio P. Sáfadi, MD, PhD FCM da Santa Casa de São Paulo Outline of the presentation Brief overview on the burden of MD Lessons learned with plain polysaccharide
More informationWHAT S NEW WITH VACCINATIONS IN 2016?
WHAT S NEW WITH VACCINATIONS IN 2016? MenB and a Few Other Changes Lynn Bahta, RN, PHN Immunization Clinical Consultant Minnesota Department of Health May 2016 Disclosure No conflict of interest Will discuss
More informationImmunizations June 5, Brenda Ormesher, MD Infectious Disease Peacehealth Medical Group Springfield, OR
Immunizations June 5, 2015 Brenda Ormesher, MD Infectious Disease Peacehealth Medical Group Springfield, OR Disclosures None Goals Understand basic public health impact of immunization Recognize types
More informationA combined approach to assess the potential coverage of a multicomponent protein-based vaccine
J prev med hyg 2012; 53: 56-60 Re v i e w A combined approach to assess the potential coverage of a multicomponent protein-based vaccine G. Boccadifuoco, B. Brunelli, M.G. Pizza, M.M. Giuliani Novartis
More informationArticles. Funding Public Health England.
Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study Sydel R Parikh, Nick J Andrews, Kazim Beebeejaun,
More informationS404- Meningococcal Vaccines: Updated Policy Statement 2014
S404- Meningococcal Vaccines: Updated Policy Statement 2014 Michael T. Brady, MD Associate Medical Director Nationwide Children s Hospital Columbus, Ohio Disclosure of Relevant Relationship Dr. Brady (or
More information2/16/2015 IMMUNIZATION UPDATE Kelly Ridgway, RPh February 21, Today s Overview NEW RECOMMENDATIONS
IMMUNIZATION UPDATE 2015 Kelly Ridgway, RPh February 21, 2015 Today s Overview 1 2 3 4 5 6 Pneumococcal Vaccine Recommendations Meningococcal Vaccine Recommendations HPV Vaccine Recommendations Patient
More informationTwo-in-one: GSK s candidate PHiD-CV dual pathogen vaccine
Two-in-one: GSK s candidate PHiD-CV dual pathogen vaccine Dr. Bernard Hoet Director, Medical affairs GlaxoSmithKline Biologicals Rixensart, Belgium Istanbul, Feb 13, 2008 PHiD-CV: A novel concept in Bacterial
More informationImmunization Update 2015
Immunization Update 2015 William Atkinson, MD, MPH* California Immunization Coalition Summit Riverside, California April 26, 2015 *Representing the Immunization Action Coalition, Saint Paul, MN Advisory
More informationSee Spot Run Meningococcal update 2017
See Spot Run Meningococcal update 2017 Jim Buttery Infection and Immunity Monash Children s Hospital Monash Health Monash University SAEFVIC How serious a disease is N meningitidis? Meningococcal disease
More informationBexsero (Meningococcal Group B Vaccine)
Bexsero (Meningococcal Group B Vaccine) Approved in More Than 35 Countries The two decade journey to bring Bexsero to Market Exploratory Pre-Clinical Development of a meningococcal group B vaccine was
More informationAdvisory Committee on Immunization Practices VACCINE ACRONYMS
May 1, 2015 Vaccine Acronyms Page 1 of 5 Advisy Committee on Immunization Practices VACCINE ACRONYMS Vaccines Included in the Immunization Schedules f Children, Adolescents, and Adults Following is a table
More informationNHS public health functions agreement Service specification No.6 Meningococcal C (MenC) containing vaccine immunisation programme
NHS public health functions agreement 2018-19 Service specification No.6 Meningococcal C (MenC) containing vaccine immunisation programme 1 NHS public health functions agreement 2018-19 Service specification
More informationMeningococci and meningococcal disease
Australian Technical Advisory Group on Immunisation (ATAGI) Statement Advice for immunisation providers regarding the use of Bexsero a recombinant multicomponent meningococcal B vaccine (4CMenB) March
More informationChanges to the Meningococcal C conjugate (MenC) vaccine schedule. Questions and Answers
Changes to the Meningococcal C conjugate (MenC) vaccine schedule Questions and Answers Background The meningococcal C (MenC) vaccination programme was first introduced into the UK routine immunisation
More information2016 Academic Review for the New Zealand National Immunisation Schedule: Pneumococcal ten valent vaccine effectiveness and safety
2016 Academic Review for the New Zealand National Immunisation Schedule: Pneumococcal ten valent vaccine effectiveness and safety Prepared as part of a Ministry of Health contract for services by the Immunisation
More information- Infanrix hexa (DTPa-HBV-IPV/Hib): GSK Biologicals combined diphtheria, tetanus, acellular pertussis, hepatitis
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationChanges to the meningococcal C conjugate (MenC) vaccine schedule 2014 first-time university entrants under the age of 25
Changes to the meningococcal C conjugate (MenC) vaccine schedule 2014 first-time university entrants under the age of 25 An update for registered healthcare practitioners August 2014 Quality Education
More information(Version 1.0, Dated 13 December 2013)
Preventing secondary cases of invasive meningococcal capsular group B disease: benefits of offering vaccination in addition to antibiotic chemoprophylaxis to close contacts of cases in the household, in
More informationNHS public health functions agreement
NHS public health functions agreement 2016-17 Service specification No. 31 Meningococcal group B (MenB) programme Classification: official NHS England INFORMATION READER BOX Directorate Medical Commissioning
More informationReview Article Conjugate Meningococcal Vaccines Development: GSK Biologicals Experience
SAGE-Hindawi Access to Research Advances in Preventive Medicine Volume 2011, Article ID 846756, 17 pages doi:10.4061/2011/846756 Review Article Conjugate Meningococcal Vaccines Development: GSK Biologicals
More informationMeningococcal vaccine evolution*
J prev med hyg 2012; 53: 131-135 through childhood to a peak in 19-year-olds, who have a carriage rate of 20%, and declines in adulthood [7, 8]. Based on the chemical composition of the polysaccharide
More informationImmunization Update & focus on meningococcal vaccine PART 2
Immunization Update & focus on meningococcal vaccine PART 2 Gregory Hussey Vaccines for Africa Initiative Institute of Infectious Diseases University of Cape Town www.vacfa.uct.ac.za Meningococcal Disease
More informationDisclosure Statement. Encapsulated Bacteria. Functions of the Spleen 10/25/2017. Pharmacist Learning Objectives
Pharmacist Learning Objectives No Spleen? No Problem. A Review of Vaccinations Indicated for the Asplenic Patient SCSHP Fall Meeting October 26, 2017 Explain the rationale for vaccinations in Select the
More informationSerogroup W in Africa & travellers
Serogroup W in Africa & travellers Muhamed-Kheir TAHA Institut Pasteur 01/11/2016 2 childhood meningococcal meningitis caused by this serogroup. Three infants, two with bacteremia and one with septic arthritis
More information1.3 Meningococcal Disease (Neisseria meningitidis) (invasive)
1.3 Meningococcal Disease (Neisseria meningitidis) (invasive) Summary Number of cases, 214: 82 Number of cases, 213: 81 Number of cases, 212: 66 Crude incidence rate, 214:1.8/1, Between and 212, a marked
More informationWhose Calling the Shots? - A 2019 Vaccine Update. Frank Bell Swedish Pediatric Infectious Disease Jan 2019
Whose Calling the Shots? - A 2019 Vaccine Update Frank Bell Swedish Pediatric Infectious Disease Jan 2019 2019 Vaccine Update Vaccines Meningococcal serogroup B HPV Pertussis Influenza Children with uncertain
More informationEarly release, published at on September 23, Subject to revision.
Early release, published at www.cmaj.ca on September 23, 2013. Subject to revision. CMAJ Research Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal
More informationHyporesponsiveness: Time To Stop Using Meningococcal Polysaccharide Vaccines?
Hyporesponsiveness: Time To Stop Using Meningococcal Polysaccharide Vaccines? Lee H. Harrison, M.D. Professor of Medicine and Epidemiology University of Pittsburgh First Regional Meningococcal Symposium
More informationAndrew Kroger, MD, MPH National Center for Immunization and Respiratory Diseases MCH & Immunization Conference Anchorage, AK September 28, 2010
2010 Immunization Update Andrew Kroger, MD, MPH National Center for Immunization and Respiratory Diseases MCH & Immunization Conference Anchorage, AK September 28, 2010 Disclosures No financial conflict
More informationAnnex 3 Recommendations for the production and control of group C meningococcal conjugate vaccines (Addendum 2003)
World Health Organization WHO Technical Report Series, No. 926, 2004 Annex 3 Recommendations for the production and control of group C meningococcal conjugate vaccines (Addendum 2003) At its fifty-second
More informationIntroduction of a meningococcal ACWY immunisation programme for adolescents
Introduction of a meningococcal ACWY immunisation programme for adolescents Information for registered healthcare practitioners Acknowledgement: This resource has been adapted with the permission of Public
More informationExpanded Use of PCV13 & PPV23
Expanded Use of PCV13 & PPV23 Dr. Jim Kellner Professor & Head Department of Pediatrics University of Calgary & Calgary Zone, Alberta Health Services Jim.Kellner@ahs.ca Objectives Explain the differences
More informationfor the New Zealand National Immunisation Schedule: Pneumococcal Auckland UniServices Limited A wholly owned company of The University of Auckland
2012 Antigen Review for the New Zealand National Immunisation Schedule: Pneumococcal Auckland UniServices Limited A wholly owned company of The University of Auckland Prepared for: New Zealand Ministry
More informationHans Jürgen Dornbusch
Epidemiology of Invasive Meningococcal Disease Hans Jürgen Dornbusch Infectious Vaccination Disease Working Working Group Group Severe bacterial infections Pneumococcus Haemophilus influenzae b 3 rd World!
More informationPREVENTION OF MENINGOCOCCAL MENINGITIS BY VACCINATION IN THE AFRICAN MENINGITIS BELT
PREVENTION OF MENINGOCOCCAL MENINGITIS BY VACCINATION IN THE AFRICAN MENINGITIS BELT Brian Greenwood London School of Hygiene & Tropical Medicine ADVAC, Annecy May 19 th 2014 Cytoplasmic proteins bacterium
More informationBackground Rationale of resource Please note:
Background In 2010, the Joint Committee on Vaccination and Immunisation (JCVI) convened a meningococcal subcommittee to conduct a comprehensive and detailed assessment of the evidence on the meningococcal
More informationPRODUCT MONOGRAPH BEXSERO. Multicomponent Meningococcal B Vaccine (recombinant, adsorbed) BEXSERO Suspension for Injection
PRODUCT MONOGRAPH BEXSERO Multicomponent Meningococcal B Vaccine (recombinant, adsorbed) BEXSERO Suspension for Injection Active Immunizing Agent for the Prevention of Meningococcal Disease ATC Code: J07AH09
More informationQ21. Where can I find more information on meningococcal disease and vaccines?
FREQUENTLY ASKED QUESTIONS This fact sheet provides responses to some common questions about meningococcal vaccines, focusing on quadrivalent meningococcal conjugate vaccines (4vMenCVs). More detailed
More informationAn Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)
+ An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) Advice for the use of the Multicomponent Meningococcal Serogroup B (4CMenB) Vaccine TO PROMOTE AND PROTECT THE
More informationMODELLING INFECTIOUS DISEASES. Lorenzo Argante GSK Vaccines, Siena
MODELLING INFECTIOUS DISEASES Lorenzo Argante GSK Vaccines, Siena lorenzo.x.argante@gmail.com GSK IN A NUTSHELL GSK VACCINES - GLOBAL PRESENCE SIENA RESEARCH AND DEVELOPMENT (R&D) SITE EXPLORATORY DATA
More informationPNEUMONIA : PROMISE FULFILLED? Regina Berba MD FPSMID
PNEUMONIA : PROMISE FULFILLED? Regina Berba MD FPSMID Objectives of Lecture Know the quality of current evidence based guidelines on immunization Appreciate the performance of pneumonia vaccines in terns
More informationWhy is surveillance important after introducing vaccines?
Why is surveillance important after introducing vaccines? Dr Michael Edelstein Immunisation Department, National Infections service Public Health England @epi_michael BSAC Spring conference, 12 th March
More informationAn Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) Literature review on serogroup B invasive meningococcal
An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) Literature review on serogroup B invasive meningococcal disease: epidemiology, multicomponent meningococcal B vaccine
More informationWould a combined PCV10+PCV13 immunization schedule be a cost-effective option for Canadian children?
Would a combined PCV10+PCV13 immunization schedule be a cost-effective option for Canadian children? Philippe De Wals Department of Social and Preventive Medicine, Laval University Quebec University Hospital
More informationImpact of MenAfriVac in nine countries of the African meningitis belt, : an analysis of surveillance data
Impact of MenAfriVac in nine countries of the African meningitis belt, 2010 15: an analysis of surveillance data Caroline L Trotter, Clément Lingani, Katya Fernandez, Laura V Cooper, André Bita, Carol
More informationFull public health impact or. cherry-picking?
Full public health impact or cherry-picking? Arto Palmu, MD, PhD, Research manager, head of Clinical Research Team, Department of Public Health Solutions 10.11.2017 Arto Palmu / RIVM2017 1 Disclosure The
More informationTo demonstrate that DTPa-HBV-IPV/Hib-MenC-TT co-administered with 10Pn, is non-inferior to DTPa-HBV-IPV/Hib coadministered
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPneumococcal Disease and Pneumococcal Vaccines
Pneumococcal Disease and Epidemiology and Prevention of - Preventable Diseases Note to presenters: Images of vaccine-preventable diseases are available from the Immunization Action Coalition website at
More informationBabyJabs Vaccines. All vaccines are mercury- free We use aluminium- free vaccines wherever possible
BabyJabs Vaccines All vaccines are mercury- free We use aluminium- free vaccines wherever possible BabyJabs is a dedicated children s immunisation service, offering a choice of single and small combination
More informationImmunization Update 2015
Immunization Update 2015 William Atkinson, MD, MPH Immunization Action Coalition Kentucky Immunization Conference Louisville, Kentucky October 14, 2015 Information in this presentation are valid as of
More informationNHS public health functions agreement Service specification No. 31 Meningococcal group B (MenB) programme
NHS public health functions agreement 2017-18 Service specification No. 31 Meningococcal group B (MenB) programme Classification: official NHS public health functions agreement 2017-18 Service specification
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPublished by Centers for Disease Control (CDC) Archived on this site by permission of CDC, [url]http://www.cdc.gov/ncidod/eid[/url]
MSF Field Research Continuing effectiveness of serogroup a meningococcal conjugate vaccine, Chad, 2013 Authors Gamougam, K; Daugla, D M; Toralta, J; Ngadoua, C; Fermon, F; Page, A-L; Djingarey, M H; Caugant,
More informationADI_Res_Bull_2013_Pneumococcal_Vaccine_Tests
ADI_Res_Bull_2013_Pneumococcal_Vaccine_Tests Most non-vaccinated humans and some animals have a natural exposure to non-virulent strains Streptococcus pneumonia, and therefore contain high levels of antibodies
More informationPotential Impact of Conjugate Vaccine on the Incidence of Invasive Pneumococcal Disease among Children in Scotland
JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 2006, p. 1224 1228 Vol. 44, No. 4 0095-1137/06/$08.00 0 doi:10.1128/jcm.44.4.1224 1228.2006 Copyright 2006, American Society for Microbiology. All Rights Reserved.
More informationChanges to the meningococcal C conjugate (MenC) vaccine schedule 2014 first-time university entrants under the age of 25 An update for registered
Changes to the meningococcal C conjugate (MenC) vaccine schedule 2014 first-time university entrants under the age of 25 An update for registered healthcare practitioners Frequently asked questions August
More informationHaemophilus influenzae
Haemophilus influenzae type b Severe bacterial infection, particularly among infants During late 19th century believed to cause influenza Immunology and microbiology clarified in 1930s Haemophilus influenzae
More informationBabyJabs Vaccines. All vaccines are mercury-free We use aluminium-free vaccines wherever possible
BabyJabs Vaccines All vaccines are mercury-free We use aluminium-free vaccines wherever possible BabyJabs is a dedicated children s immunisation service, offering a choice of single and small combination
More informationImpact of meningococcal C conjugate vaccine in the UK
J. Med. Microbiol. Vol. 51 (22), 717 722 # 22 Society for General Microbiology ISSN 22-2615 REVIEW ARTICLE Impact of meningococcal C conjugate vaccine in the UK P. BALMER, R. BORROW and E. MILLER Meningococcal
More informationVaccine Description Administration Re-vaccination Pneumococcal Vaccines Prevnar 13 (PCV 13)
Guideline for the Vaccination of Patients with Splenic Injury Requiring Splenectomy or Splenic Embolization This guideline is written for individuals 12 years and older admitted to the Maine Medical Center
More informationShelter-based Meningococcal Disease Outbreak: Working together to treat and vaccinate
Shelter-based Meningococcal Disease Outbreak: Working together to treat and vaccinate Barbara Giles, MSN, RN April Donahue, BSN, RN Denise De Las Nueces, MD, MPH Boston Health Care for the Homeless Program
More informationMENINGITIS WHAT S NEW? 3 RD NOVEMBER 2018
MENINGITIS WHAT S NEW? 3 RD NOVEMBER 2018 CONFLICTS OF INTEREST Educational travel grant - Gilead JIM NEWCOMBE FRCPA FRACP ID PHYSICIAN, ROYAL NORTH SHORE HOSPITAL, SYDNEY CLINICAL MICROBIOLOGIST, DOUGLASS
More informationRecommendations for the production and control of group C meningococcal conjugate vaccines
Technical Report Series No. 1 Recommendations for the production and control of group C meningococcal conjugate vaccines Addendum 2003 The Expert Committee on Biological Standardization, at its fifty-second
More informationGlobal Burden of Meningococcal Disease. Prof. David Salisbury CB FRCP FRCPCH FFPH FMedSci. Centre for Global Health Security, Chatham House, London.
Global Burden of Meningococcal Disease Prof. David Salisbury CB FRCP FRCPCH FFPH FMedSci. Centre for Global Health Security, Chatham House, London. Neisseria meningitidis Gram negative diplococci. Ten
More informationPneumococcal Vaccine Introductions Dr. Carsten Mantel WHO/FCH/IVB/EPI
Pneumococcal Vaccine Introductions 2012 Dr. Carsten Mantel WHO/FCH/IVB/EPI Pneumonia is leading cause of death in children < 5 yrs * Pneumococcus and Hib are the two leading causes of life-threatening
More informationPneumococcal vaccines. Safety & Efficacy. Prof. Rajesh Kumar, MD PGIMER School of Public Health Chandigarh
Pneumococcal vaccines Safety & Efficacy Prof. Rajesh Kumar, MD PGIMER School of Public Health Chandigarh Disclosure Slide X X I DO NOT have any significant or other financial relationships with industry
More informationImmunisation against meningococcal B disease for infants aged from two months. Information for registered health care practitioners
Draft 6thJuly Immunisation against meningococcal B disease for infants aged from two months Information for registered health care practitioners Disclaimer These draft training resources have been prepared
More informationAn AW outer membrane vesicle (OMV) meningococcal vaccine trial in Ethiopia. Tesfamariam Mebrahtu Armauer Hansen Research Insitute
An AW outer membrane vesicle (OMV) meningococcal vaccine trial in Ethiopia Tesfamariam Mebrahtu Armauer Hansen Research Insitute BACKGROUND meningitis belt In the meningitis belt of sub-saharan Africa
More informationBabyJabs Vaccines. All vaccines are mercury-free We use aluminium-free vaccines wherever possible
BabyJabs Vaccines All vaccines are mercury-free We use aluminium-free vaccines wherever possible BabyJabs is a dedicated children s immunisation service, offering a choice of single and small combination
More informationNeisseria meningitidis B vaccines
Expert Review of Vaccines ISSN: 1476-0584 (Print) 1744-8395 (Online) Journal homepage: http://www.tandfonline.com/loi/ierv20 Neisseria meningitidis B vaccines Donatella Panatto, Daniela Amicizia, Piero
More informationPRODUCT MONOGRAPH BEXSERO. Multicomponent Meningococcal B Vaccine (recombinant, adsorbed) BEXSERO Suspension for Injection
PRODUCT MONOGRAPH BEXSERO Multicomponent Meningococcal B Vaccine (recombinant, adsorbed) BEXSERO Suspension for Injection Active Immunizing Agent for the Prevention of Meningococcal Disease ATC Code: J07AH09
More informationMeningitis January Dr Andrew Lee Consultant in Communicable Disease Control, PHE Information in this slide set was correct as of 21.1.
Meningitis January 2016 Dr Andrew Lee Consultant in Communicable Disease Control, PHE Information in this slide set was correct as of 21.1.16 Outline What is meningitis What causes it What are the signs
More informationImmunization Update: New CDC Recommendations. Blaise L. Congeni M.D. 2012
Immunization Update: New CDC Recommendations Blaise L. Congeni M.D. 2012 Polysaccharide Vaccines Vaccine Hib capsule polysaccharide PRP (polyribose ribitol phosphate) Not protective in infants
More informationPneumococcal Vaccines The Impact Of Conjugate Vaccine
Pneumococcal Vaccines The Impact Of Conjugate Vaccine 1 / 5 2 / 5 3 / 5 Pneumococcal Vaccines The Impact Of Pneumococcal vaccine. The pneumococcal vaccine protects against serious and potentially fatal
More informationKeeping up with the immunization schedule: Meningococcal and More
Keeping up with the immunization schedule: Meningococcal and More DatTran, MD, MSc, FRCPC, FAAP Division of Infectious Diseases, The Hospital for Sick Children Department of Paediatrics, University of
More informationBackground In 2010, the Joint Committee on Vaccination and Immunisation (JCVI) convened a meningococcal subcommittee to conduct a comprehensive and
Background In 2010, the Joint Committee on Vaccination and Immunisation (JCVI) convened a meningococcal subcommittee to conduct a comprehensive and detailed assessment of the evidence on the meningococcal
More informationNational Institute for Communicable Diseases -- Weekly Surveillance Report --
Weekly Surveillance Report Week 43, 216 National Institute for Communicable Diseases -- Weekly Surveillance Report -- Page 2 Laboratory-Based Respiratory & Meningeal Disease Surveillance 3 Neisseria meningitidis
More informationMeningococcal Disease in Travellers
Meningococcal Disease in Travellers Please find product Prescribing Information at the end of this presentation Meningococcal disease A rare but potentially serious illness in travellers1 Caused by the
More informationShabir A. Madhi. Global Overview of Maternal Immunisation
Shabir A. Madhi Global Overview of Maternal Immunisation National Institute for Communicable Diseases & University of Witwatersrand, South Africa Respiratory and Meningeal Pathogens Research Unit, & DST/NRF:
More information